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Abstract
Schizophrenia, a mental disorder that is characterized by abnormal social behavior and failure to distinguish
one’s own thoughts and ideas from reality, has been associated with structural abnormalities in the architecture
of functional brain networks. Using various methods from network analysis, we examine the effect of two classi-
cal therapeutic antipsychotics — Aripiprazole and Sulpiride — on the structure of functional brain networks of
healthy controls and patients who have been diagnosed with schizophrenia. We compare the community struc-
tures of functional brain networks of different individuals using mesoscopic response functions, which measure
how community structure changes across different scales of a network. We are able to do a reasonably good job
of distinguishing patients from controls, and we are most successful at this task on people who have been treated
with Aripiprazole. We demonstrate that this increased separation between patients and controls is related only to
a change in the control group, as the functional brain networks of the patient group appear to be predominantly
unaffected by this drug. This suggests that Aripiprazole has a significant and measurable effect on community
structure in healthy individuals but not in individuals who are diagnosed with schizophrenia. In contrast, we
find for individuals are given the drug Sulpiride that it is more difficult to separate the networks of patients
from those of controls. Overall, we observe differences in the effects of the drugs (and a placebo) on community
structure in patients and controls and also that this effect differs across groups. We thereby demonstrate that
different types of antipsychotic drugs selectively affect mesoscale structures of brain networks, providing support
that mesoscale structures such as communities are meaningful functional units in the brain.
1 Introduction
Investigating the structure and dynamics of neuronal networks is crucial for understanding the human brain, and
the nascent field of “network neuroscience” has yielded fascinating insights into a diverse variety of neurological
phenomena [1, 2]. Recent advances in imaging technology have made it possible to perform increasingly detailed
analyses of brains, and it is now possible to map anatomical regions and their interconnecting pathways at near-
millimeter resolution. This yields large-scale networks with which to describe the brain’s structural connectivity
(i.e., the human connectome) [3, 4]. These structural connections govern large-scale neuronal dynamics, which can
be captured as patterns of functional connectivity in so-called “functional brain networks” [5–8]. Such functional
networks are usually built by estimating dynamical correlations or other interdependencies in the neuronal activity
of brain regions.
One can measure functional brain networks using various approaches, such as through blood oxygen level de-
pendent (BOLD) signals gathered via functional magnetic resonance image (fMRI) scans or using other modali-
ties [1, 2, 4, 7]. Such studies have yielded many fascinating insights, such as successful detection of irregularities in
fMRI data of patients with disorders and diseases like Alzheimer’s disease [9], autism [10], schizophrenia [11–13],
and others [14].
In the present paper, we seek to analyze the specific role and effect that different antipsychotics (specifically,
Aripiprazole and Sulpiride) play in the structure — especially community structure, in which densely-connected
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sets of nodes are relatively sparsely connected to other densely-connected sets of nodes [15–17] — of functional
brain networks of both control and patients. Schizophrenia is often characterized by abnormal and inconsistent
social behavior and failure to differentiate between thoughts and reality. Methods for diagnosing schizophrenia have
been somewhat controversial [18], and scientists and doctors seek to understand and develop effective diagnoses
and treatment (in the form of therapy and drugs) [19]. The atypical antipshchotic drug Aripiprazole, which acts
as a partial dopamine agonist, is used primarily for the treatment of schizophrenia. Sulpiride, another atypical
antipsychotic that works as a selective dopamine agonist, is also used to treat schizophrenia. Their effectiveness has
been reported widely in the literature, and their use for treatment has been approved in many countries [20, 21].
(We note, however, that Sulpiride is not approved for use in the United States, Canada, or Australia.)
It has been hypothesized that schizophrenia is related to abnormalities in the connectivity between components
of functional brain networks [11]. Furthermore, although the biological mechanisms of Aripiprazole and Sulpiride
are well-understood, their effects at the functional level of the brain are not. This motivates our goal to explore the
fingerprint of such drugs in functional brain networks. An important property of a functional brain network, which
appears to be abnormally altered in patients diagnosed with schizophrenia, is community structure [2,22]. Loosely
speaking, a community is a set of nodes in a network that are connected densely to each other but connected sparsely
to other parts of a network [15, 16]. Community structure in a network is one type of mesoscale organization, and
both community structure and other mesoscale organizations (e.g., core–periphery structure [23]) are important in
a variety of contexts in functional brain networks [2].
To examine community structure in healthy individuals versus individuals with schizophrenia under the effects
of different drugs, we employ several characterizations of graph similarity. We consider both basic features (such as
the number of common edges) and more sophisticated ones (such as how community structure changes over different
scales of a network [24]). This suite of techniques allows us to build a set of distance matrices between subjects, and
we apply unsupervised clustering algorithms to these matrices to try to identify discernible groups of subjects. We
focus in particular on studying the effects of each drug within a given group (intra-subject comparisons), though we
also compare groups under the same drug (inter-subject comparisons). We thereby investigate both the difference
between healthy subjects and patients and the effects that each of the drugs have on the functional brain networks
of each group of subjects.
The rest of our paper is organized as follows. In Section 2, we briefly discuss the data set and some relevant
previous studies. In Section 3, we detail the protocol and the methods that we use to make comparisons between
groups of subjects. In Section 4, we present our results. Finally, in Section 5, we discuss the implications of our
findings. In an appendix, we state and prove a theorem (that a certain diagnostic has a metric structure) that we
use in the main text.
2 Data and Previous Studies
The data set, which came from Bristol Myers Squibb (BMS) and which we call the “BMS data set”, consists of
measurements of 15 healthy human subjects (“controls”) and 12 human subjects (“patients”) who were diagnosed
previously with schizophrenia. All participants were pre-treated with domperidone on all three days to reduce side
effects. Over 3 sessions, which were 1–2 weeks apart, each of the 27 subjects was given one of three different drug
treatments:
1. (“Placebo”) Oral placebo, 180 and 90 minutes before scanning;
2. (“Sulpiride”) Oral placebo, 180 minutes before scanning; and then oral Sulpiride (400 mg), 90 minutes before
scanning;
3. (“Aripiprazole”) Oral Aripiprazole (15 mg), 180 minutes before scanning; and then oral placebo, 90 minutes
before scanning.
At each session, after being given one of the drug treatments, each individual was placed in an fMRI scanner to
measure blood flow in the brain. The fMRI scanner captures a single image once every 2 seconds. The scans lasted
17 minutes and 4 seconds, so each BOLD time series has 512 time points. The data are parcellated into 298 regions
of interest (RoIs), and each region corresponds to a node in a functional brain network. The parcellation is based
on an existing method, but with 27 regions removed due to problems with head motion [25, 26]. Each region has
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a corresponding time series that represents an average level of activity in that region. We remove 4 controls (2, 8,
10, and 14) and 3 patients (3, 5, and 11) from our calculations due to missing data and/or problems due to head
motion. We thus examine a total of 20 subjects: 11 controls and 9 patients. See [27–29] for discussions of issues
with head motion, and see [26,30] for discussions of preprocessing of fMRI data to correct for head motion.
There have been three previous studies [11,31,32] that employed this particular data set. They dealt solely with
the task of distinguishing controls from patients who had been diagnosed with schizophrenia, so they were trying to
find effective biomarkers for schizophrenia. Using a parcellation with 90 RoIs, Ref. [11] reported that the patients
have “less strongly connected” brain networks (i.e., in the sense of a lower mean pairwise wavelet coherence between
regions) and “more diverse” profiles (in the sense of larger mean variances in a wavelet coherence between a given
region and the others) of brain functional connectivity than the controls. They also calculated that brain networks
in the schizophrenia group have a greater robustness to uniform-at-random removal of nodes, in the sense that the
number of nodes in the largest connected component (LCC) decays more slowly as a function of the number of
removed nodes. Reference [31] built functional networks via “spatial pairwise clustering” (a novel approach that
they introduced) of individual voxels (thereby foregoing the need to choose a parcellation) and combining spatially
proximate voxels into nodes. In their computations, they observed weaker inter-nodal correlations in patients than
in controls. Finally, using a very similar parcellation to the one that we employ, a very recent work [32] studied the
effects of the drugs on the networks of the subjects. Their results suggest that (1) Aripiprazole has a major effect
on the networks of healthy people and that (2) both drugs make it harder to distinguish controls and patients.
3 Methods and Preliminary Computations
We illustrate our analysis pipeline in Fig. 1. In Subsections 3.1 and 3.2, we briefly describe how to build a
functional network from fMRI time series using wavelet correlations and thresholding techniques (step 1 in Fig. 1).
In Subsection 3.3, we discuss our preliminary computations on the collection of networks. In Subsections 3.4 and 3.5,
we discuss how to define two distance functions to examine dissimilarities of functional networks (step 2 in Fig. 1)
and how to apply hierarchical clustering to cluster similar subjects (i.e., similar functional networks) according to
step 3 in Fig. 1).
3.1 Building the Networks
Wavelet-based correlations allow one to examine functional similarities between brain regions based on activity in a
specified frequency interval (a so-called wavelet “scale”). We use the maximal-overlap discrete wavelet transform [33]
to decompose each regional mean fMRI time series (see step 1 in Fig. 1). Examining wavelets is useful for studying
resting-state fMRI data, and functional connectivity between regions is typically largest at certain frequency bands
(below 0.1 Hz) [34]. Let gi denote the time series of node (i.e., RoI) i (where i ∈ {1, 2, . . . , 298}), and let Vs(gi)
denote the vector of scale-s wavelet coefficients of gi. At scale s, the connection strength between two nodes i and
j in a functional network is given by the wavelet correlation
Fij =
∑
k Vs,k(gi)Vs,k(gj)√
(
∑
k(Vs,k(gi))
2(
∑
k(Vs,k(gj))
2
∈ [−1, 1] . (1)
Fe compute values of Fij for scales s = 1, 2, 3, 4; and we then choose to work with the most informative scale (see
Section 4).
There are N = 298 RoIs for each subject, so we extract functional networks with N = 298 nodes. This yields
a similarity matrix F whose elements are given by Eq. (1). To avoid negative weights1, we transform F into a
weighted adjacency matrix W by taking Wij := (Fij + 1)/2 ∈ [0, 1]. The associated network is fully connected by
construction, and there are two customary ways to prune edges. These are (1) thresholding the networks by keeping
a fixed fraction τ of the strongest weights (assigning the remaining edges a weight of 0 and producing thresholded
weighted networks) and (2) first performing the previous step and then subsequently setting the remaining edges a
1There are also other ways to transform F into a weighted adjacency matrix W. For example, one can take the absolute value of
the correlations, though it is then impossible to distinguish negative wavelet similarities from positive ones. The weakness of our chosen
approach is that initially strongly negative weights are transformed into weights that are near 0, and they then tend to be removed if
one subsequently prunes a network by keeping only the most strongly weighted edges ofW. Recently, [35] examined the significance of
such negative wavelet similarities.
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Figure 1: Protocol to obtain a dendrogram that conveys hierarchical clustering of a set of subjects. The submatrix that we
use depends on our particular comparison from Fig. 5. We explain the vertical axis in the dendrogram in Section 3.4.2. In
the example dendrogram in this schematic, we consider unweighted networks that the include strongest 20% edges (see Section
3.1).
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weight of 1, thereby producing thresholded binary networks. In both cases, the resulting thresholded networks have
E = N(N − 1)τ/2 edges. Of course, one can also simply keep all edges and examine the original fully connected,
weighted networks. In the present paper, we initially examine the original networks and both the weighted and
binary thresholded networks. Based on some preliminary calculations, we then decide which of these networks to
examine further.
3.2 Choosing a Scale and Thresholding Parameter
To construct the functional networks, we choose a scale s and then consider thresholding the networks (with an
associated threshold value). Previous work has noted differences in both “connectivity” (i.e., the mean edge weight of
a network) and mean local clustering coefficient between healthy controls and patients with schizophrenia [11,36,37].
The observed difference were more statistically significant at lower frequencies, and it was particular evident at scale
2. This is consistent with previous research on resting-state fMRI [38]. To make an educated choice of scale, Ref. [11]
calculated the mean value of Fij over healthy controls and patients for each scale, performed a t-test, and selected
the scale with the smallest p-value. We follow a similar procedure, but we also threshold the networks for both
binary and weighted versions using a thresholding parameter τ , in which we keep a fraction τ of the strongest edges.2
(For example, if τ = 0.4, we keep the strongest 40% of the edges.) For each of the three drug treatments and for
each of the scales 1, 2, 3, and 4, we then perform a t-test on the mean local clustering coefficients of healthy controls
and patients diagnosed with schizophrenia. In Fig. 2, we show all 12 plots and the p-values associated with the
t-tests. Based on these results, we make two decisions. First, from now on, we use scale 2 (which corresponds to the
frequency band 0.060–0.125 Hz), because it has the smallest p-values (in agreement with previous work [11]). For
very small values of τ , we observe spikes in the p-values that likely arise from the networks breaking up into many
components. Second, because our results on binary networks have smaller p-values than the corresponding ones for
weighted networks, we focus our subsequent calculations on thresholded binary networks (except for our calculations
of connectivity). The controls tend to have much larger edge weights than the patients, so our comparisons between
patients and controls are more directly parallel if we use binary networks, as many network quantities are affected in
nontrivial ways by edge weights. From now on, we fix τ = 0.2. (We repeat our calculations for values of τ ∈ [0.2, 0.4],
and we obtain qualitatively similar results.)
Half of our networks (30 out of 60) have more than one component when τ = 0.2. This can be problematic
for some types of computations, such as those that involve path lengths, but this issue has not posed a problem in
practice in the present work, and the largest connected component of every network has at least 291 nodes (out of
298 nodes in total). In Appendix B, we show the number and sizes (i.e., number of nodes) of the components in
each of our networks.
3.3 Connectivity and Mean Local Clustering Coefficient
We now do some preliminary calculations. Previous research using thresholded, binary networks has highlighted
significant differences in “connectivity” (defined, for an individual subject, as the mean edge weight 〈Wij〉 of a net-
work) and mean local clustering coefficients of networks from control subjects versus those from patients diagnosed
with schizophrenia [11]. In our case, by construction, connectivity corresponds (up to a scaling and a shift) to the
mean wavelet correlation. For weighted networks, we compute the weighted local clustering coefficient [39]
ci =
1
ki(ki − 1)
∑
j,k
(WijWikWjk)
1/3 for ki ≥ 2 , (2)
where ki is the degree of node i, and ci = 0 if ki ∈ {0, 1}. Equation (2) reduces to the usual local clustering
coefficient for the special case of binary networks.
For connectivity, we calculate 〈Wij〉 for each subject, and we then calculate the means for both controls and
patients. We follow the same process for the clustering coefficient. In our preliminary analysis, we explore how
these basic quantities differ for different drug treatments. Specifically, we calculate connectivity using the non-
thresholded weighted versions of the networks and mean local clustering using the thresholded binary networks.
We show our results in Fig. 3, where for each case we plot the mean and standard deviation across subjects. For
each drug treatment, we also perform a two-sample t-test on the values of connectivity and mean local clustering
2We consider values of τ in increments of 0.01.
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Figure 2: The p-values associated with t-tests on the mean local clustering coefficient (between healthy patients and controls)
for weighted networks (solid red curves) and binary networks (blue dashed curves) for different values of the thresholding
parameter τ . Wavelet scale 2 produces the smallest p-values. We also observe a difference in the curves of the three drug
treatments and that the p-values associated with the binary networks are consistently smaller than those for the weighted ones.
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coefficients for controls and patients, and we extract a p-value. We observe small differences in connectivity and
mean local clustering coefficients between controls and patients; this difference is smaller than what was reported
previously with these data using other approaches [11]. We also observe that Aripiprazole has a small effect on
the connectivity and mean local clustering coefficients of healthy controls but no significant effect on patients, in
agreement with other recent work [32]. Sulpiride appears to have little effect on either group, though we observe a
larger difference between controls and patients for mean local clustering coefficient than we do for connectivity. We
obtain a p-value of p ≈ 0.0326 for mean local clustering coefficient and a p-value of p ≈ 0.1680 for connectivity. We
show the connectivity for all subjects under Placebo in Fig. 4, and we note that Patient 8 has very high connectivity.
However, given the sizes of the error bars, we cannot reject the hypotheses that the connectivity and/or mean local
clustering coefficients are indistinguishable in the different situations. This suggests that — at least for this data
set — these simple network diagnostics do not give clear information about whether the drugs have any effects
on the structure of functional brain networks. Given the inconclusiveness of these results, we need to do a more
sophisticated analysis,
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Figure 3: Means and standard deviations of (left) connectivity for non-thresholded weighted networks and (right) mean local
clustering coefficients for binary networks thresholded to 20% of the strongest edges. The results are similar in each case,
though for Sulpiride we observe a difference between controls and patients in the p-value for the two-sample t-test.
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Figure 4: Connectivity for all subjects under Placebo. Note that Patient 8 has an abnormally high connectivity.
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3.4 Distance Measures
As we mentioned in Section 1, we aim to classify similar functional brain networks using unsupervised clustering of
subjects. A subject is represented by a functional network, so to do this in a systematic way, we define a pairwise
distance function between graphs, and we then use this function to compute a distance matrix for a set of subjects.
(See step 2 in Fig. 1.) We consider distance functions based on two rather different aspects of networks.
3.4.1 Hadamard-like distance
One can construct a simple similarity measure between binary networks A and B that both have the same number
of edges by computing the Hadamard product of the matrices and then summing the entries AijBij of the resulting
matrix. For binary networks, this sum (
∑
i>j AijBij) is the number of common edges in the networks. Because
functional networks are usually thresholded so that one retains only a specified, fixed fractions of edges, we can use
this similarity measure to compare adjacency matrices that are extracted from thresholded functional networks.
We define the metric
d1(A,B) = 1− 1
E
∑
i>j
AijBij ∈ [0, 1] , (3)
which is well-defined when A and B have the same number E of edges.
We have proven rigorously (see Appendix A for the precise statement of the theorem and proof) that d1 satisfies
the properties of a metric. We can thus construct a distance matrix D1, whose elements D1αβ measure the distance
between the functional networks of subjects α and β. Using D1 has the advantage of being computationally efficient
and based on a mathematically sound metric, although d1 is a rather simplistic measure — two networks are more
distant from each other when they have fewer common edges — and we do not expect it to capture certain details
(e.g., community structure) of the networks.
3.4.2 Community-structure-based distance
We also use a more sophisticated distance measure, introduced by Onnela et al. [24], that is based on network
community structure [15, 16]. It requires using a method of partitioning that assigns each node to a community
(i.e., it is a “hard partition”). In the present paper, we use modularity maximization [40, 41] and employ the code
of Onnela et al., which implements the Louvain method [42].
Given a network described by its weight matrixW, one can detect communities of this network by maximizing
modularity, which one does by minimizing the objective function
H(γ) = −
∑
i 6=j
(
Wij − γ rirj
2M
)
δ(Ci, Cj) , (4)
where γ is a resolution parameter, Ci is the community assignment of node i (and Cj is the community assignment of
node j), ri is the strength (i.e., sum of incident edge weights) of node i, andM is the total edge weight. We consider
undirected networks, so we use the Newman–Girvan null-model matrix P with elements Pij = rirj/(2M) [41, 43].
For unweighted networks, node strength reduces to degree (i.e., ri = ki and rj = kj), and the total edge weight
reduces to the total number of edges (i.e., M = E). For each value γ, minimizing the objective function (4) gives a
partition of nodes into disjoint communities.
Onnela et al. examined so-called “mesoscopic response functions” (MRFs) for three quantities that describe,
from different perspectives, how a partition of a network changes as a function of γ. They calculated an effective
energy (Heff), an effective entropy (Seff), and an effective number of communities (ηeff) as functions of a resolution
parameter ξ that depends on γ. As discussed in [24], the parameter ξ tracks, in a discrete manner (keeping track of
when each effective weight changes sign), which edges have an effective positive weight and which have an effective
negative weight when the associated null-model matrix element is taken into account. A given network has a
particular profile for Heff, Seff, and ηeff (or for any other quantity that one wishes to track [44]) as a function of
ξ, and one can then compare a pair of networks based on the differences in these profiles. One can define three
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distances between a pair of networks, α and β, as follows:
dHαβ =
1ˆ
0
∣∣∣Hαeff(ξ)−Hβeff(ξ)∣∣∣ dξ , (5)
dSαβ =
1ˆ
0
∣∣∣Sαeff(ξ)− Sβeff(ξ)∣∣∣ dξ , (6)
dηαβ =
1ˆ
0
∣∣∣ηαeff(ξ)− ηβeff(ξ)∣∣∣ dξ . (7)
The trio of distances in Eqs. (5)–(7) capture different aspects of community structure. The effective energy (Heff)
is a rescaled version of the objective functionH, the effective entropy (Seff) represents the level of homogeneity in the
sizes of the detected communities, and the effective number of communities (ηeff) is a rescaled version (with respect
to network size) of the total number of communities. From these distances matrices, we construct a single distance
matrix (although one can also separately study distance matrices constructed using these, or other, distances). To
construct this distance matrix, we project each 3-dimensional coordinate using principal component analysis (PCA)
and keep the first component. In other words, we construct a distance matrix by calculating a linear combination
of the three distance measures:
dPαβ = wHd
H
αβ + wSd
S
αβ + wηd
η
αβ , (8)
where the weights w` (with ` ∈ {H,S, η}) are the coefficients of the first principal component. There are a total of
60 networks (11 controls and 9 patients, each of which is on 3 different drug treatments). We calculate the matrix
composed of 60× 59/2 (the total number of network pairs) rows and 3 columns, where each column corresponds to
the vector representation of the upper triangle of one of the distance matrices DH, DS , Dη. We perform a PCA
on this matrix to create a distance matrix DP .
The final outcome of the above calculation is a 60 × 60 distance matrix DP , where each entry measures the
distance between networks α and β based on how the community structure of each network varies as a function
of the resolution parameter ξ. We henceforth use the term “MRF distance” for the quantity that we compute in
Eq. (8).
3.5 Hierarchical Clustering
Once we have our distance matrix (see Section 3.4.2), we take a submatrix of it for each of the comparisons in
Fig. 5. For example, if we are comparing controls and patients under the drug Aripiprazole, we keep only the
rows and columns that correspond to this drug, leaving us with a 20 × 20 distance matrix, where the rows and
columns correspond to the 11 controls and 9 patients. We then cluster the new, smaller distance matrix using one of
numerous possible methods. For simplicity, we use average linkage clustering to group similar subjects (i.e., similar
networks) together and show our results in the form of dendrograms. We then order the leaves of the dendrogram to
maximize the sum of the similarities between adjacent leaves by reordering its branches (without further partitioning
clusters). We color the leaves of the dendrograms based on their annotations: patients or controls without drugs,
patients or controls on one drug, or patients and controls on the other drug.
4 Main Results
As we mentioned in Section 1 and depicted in Fig. 5, we are going to make a total of 9 comparisons, including
both inter-subject ones (different groups under the effect of the same drug) and intra-subject ones (the same group
under the effect of different drugs). In our ensuing discussions, we present the results of these comparisons.
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Figure 5: Illustration of possible comparisons between the groups of subjects and different drug treatments.
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Figure 6: Dendrogram for the drug Aripiprazole in which we compare the 11 controls and 9 patients using the distance measure
d1(A,B). There is some separation between patients and controls.
4.1 Inter-subject Comparisons
We do inter-subject comparisons using the procedure that we outlined in Fig. 1. We start by comparing controls
and patients under the effects of the drug Aripiprazole using the simple distance measure d1(A,B) from Eq. (3).
We show the resulting dendrogram in Fig. 6. We observe some separation between patients and controls.
To do a more sophisticated analysis, we then compute a dendrogram on the same data using the MRF distance
matrix DP (see Section 3.4). We show the resulting dendrogram in Fig. 7. The separation between patients and
controls is now better, and we correctly classify almost every individual. The only exception is Patient 8, who is
assigned to the same group as the controls. Although this misclassification seems surprising at first, it agrees with
our previous calculations (see Fig. 4), which also suggest that Patient 8 has different network characteristics than
the other patients.
The above result suggests that, under the drug Aripiprazole, we are able to almost completely distinguish
patients from controls, based only on information about their community structure. This also suggests that the
distance matrix DP incorporates more meaningful information than the simplistic distance measure in Eq. (3), so
we use only the former for our subsequent computations.
We show the analogous results comparing controls and patients under Placebo in the left panel of Fig. 8. In this
case, we still observe a relatively good separation between patients and controls, in agreement with previous results
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Figure 7: Dendrogram for the MRF analysis of functional brain networks for the drug Aripiprazole. We compare the 11
controls and 9 patients using the distance measure Dp . There is a clear separation between patients and controls, although
Patient 8 appears with the control group.
that functional networks encode biomarkers that separate patients diagnosed with schizophrenia from healthy
controls [11, 31]. In this situation too, Patient 8 appears to be more similar to the controls than to the other
patients. Even more interesting, we observe a less-clear separation between the controls and patients than we did
under Aripiprazole. We thus conclude that Aripiprazole alters community structure for at least one group and that
this alteration makes it easier to distinguish the patient and control groups. However, it is not obvious whether
Aripiprazole is affecting the structure of the functional brain networks of patients, controls, or both.
In the right panel of Fig. 8, we show our results for computations of functional brain networks for individuals
under the influence of Sulpiride. The control and patient groups are now less distinct from each other than they
were with Placebo. This suggests that Sulpiride has a mild but detectable effect of increasing the similarity between
the community structures of patients and controls. Again, it is not clear whether Sulpiride affects the functional
brain networks of patients, controls, or both.
4.2 Intra-subject Comparisons
To examine the effects of the drug treatments on network structure, we make intra-subject comparisons, such as
comparing the control group under Aripiprazole to the control group under Sulpiride. We do these comparisons
using the procedure that we outlined in Fig. 1.
4.2.1 Aripiprazole versus Placebo
For our intra-subject comparisons (see Fig. 5), we first compare the effect of Aripiprazole on the functional brain
networks of controls to those of patients. To do this, we use all 11 controls under Aripiprazole and the same 11
controls under Placebo and do average linkage clustering on the associated 22 × 22 distance matrix with MRF
distances. We also do average linkage clustering using the MRF distance for the 18 × 18 distance matrix that we
obtain by considering the 9 patients under Aripiprazole and the same patients under Placebo.
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Figure 8: Dendrogram for our MRF analysis of functional brain networks for (left) Placebo and (right) the drug Sulpiride.
In order of most successful to least successful (compare this figure to Fig. 7), the clustering performs best for Aripiprazole,
second-best for Placebo, and worst for Sulpiride.
In Fig. 9, we show the dendrogram for our comparison between Aripiprazole and Placebo for patients. At the
coarsest level of detail (i.e., a separation for a large MRF distance in the dendrogram), we observe that both the
Aripiprazole and Placebo network of Patient 8 is grouped away from those of the other patients. This is consistent
with our prior results: we saw in Fig. 4 that Patient 8 has a much higher connectivity than the other patients and saw
in Fig. 7 that Patient 8 was grouped with the controls. At the finest level of detail, we also find for both Aripiprazole
and Placebo that Patients 3 and 7 cluster close to each other. This suggests there is little community structure in
these patients under Aripiprazole compared to a Placebo. We thus expect, given the inter-subject comparisons in
Section 4.1, that Aripiprazole does affect community structure in controls. We confirm this hypothesis in Fig. 10,
where we observe that controls under Aripiprazole are clearly separated from controls under Placebo.
4.2.2 Sulpiride versus Placebo
In Section 4.2.1, we observed a very clear separation between controls and patients under the drug Aripiprazole and
evidence (though the situation is less clear) of separation under Placebo. We observed an even lesser separation
in Sulpiride. We hypothesized that Sulpiride has a mild but detectable effect of increasing the similarity between
community structure in patients and controls, and we therefore hypothesize that Sulpiride affects community struc-
ture of either patients or controls (or both), in agreement with [32]. In Fig. 11, we show a dendrogram of the
intra-subject comparison of Placebo versus Sulpiride in controls. We do not observe any clear clustering. We also
do not observe any clustering in the same comparison for patients (see Fig. 12). We therefore do not find any clear
indication of why Sulpiride seems to make controls and patients less distinguishable from each other. Additionally,
we do not observe a clear separation under Placebo or under Sulpiride either for controls (see Fig. 11) or for patients
(see Fig. 12).
4.2.3 Aripiprazole versus Sulpiride
We can partly distinguish controls under Aripiprazole versus Sulpiride (see Fig. 13). This is unsurprising, given
that we found (see Section 4.2.1) that Aripiprazole alters community structure in controls. We do not observe any
obvious difference for patients under Aripiprazole versus Sulpiride (see Fig. 14).
4.3 Synthesis of our Results from Hierarchical Clustering
Our results from average linkage clustering of collections of functional brain networks using the distance functions
yield the following conclusions:
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Figure 9: Dendrogram for our MRF analysis of functional brain networks for our comparison between Aripiprazole and
Placebo for the patient group. Each patient thus appears twice on the horizontal axis. There is no clear separation between
the two drugs, and some patients (e.g., 3, 7, and 8) cluster very close to themselves, suggesting there there is very little
difference in community structure in the networks under Placebo and under Aripiprazole in these patients.
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Figure 10: Dendrogram for our MRF analysis of functional brain networks for our comparison between Aripiprazole and
Placebo for the control group. We observe a clear separation between networks under the two drug treatments.
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Figure 11: Dendrogram for our MRF analysis of functional brain networks for our comparison between Sulpiride and Placebo
for the control group.
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Figure 12: Dendrogram for our MRF analysis of functional brain networks for our comparison between Sulpiride and Placebo
for the patient group. As with our comparison of Placebo to Aripiprazole, identical patients appear close together, and Patient
8 is again distant from the others.
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Figure 13: Dendrogram for our MRF analysis of functional brain networks for our comparison between Aripiprazole and
Sulpiride for the control group.
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Figure 14: Dendrogram for our MRF analysis of functional brain networks for our comparison between Aripiprazole and
Sulpiride. In both the Aripiprazole and Sulpiride networks, it is once again easy to distinguish Patient 8 from the other
patients.
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• Aripiprazole affects community structure in controls, but not in patients; and it thereby facilitates the dis-
tinction between controls and patients under the effect of this drug treatment.
• Sulpiride reduces the distinguishability between patients and controls, though our intra-subject computations
were inconclusive in both patients and controls.
5 Conclusions and Discussion
We used network analysis to examine the effects of two therapeutic antipsychotics — Aripiprazole and Sulpiride
— on the structure of functional brain networks of both healthy controls and patients who have been diagnosed
with schizophrenia. Using mesoscopic response functions, we compared community structures of functional brain
networks of these individuals under the effects of Aripiprazole, Sulpiride, and a placebo.
We will now summarize the results of our computations. However, before doing so, we stress that when interpret-
ing the results of fMRI studies, it is very important to consider the cautionary notes in [45]. These complications
notwithstanding, our computations produced several interesting results. First, we did a reasonable job of distin-
guishing between controls and patients under Placebo, and we did a much better job of distinguishing the two
groups under Aripiprazole. This suggests that Aripiprazole has a larger effect on community structure in one of
the two groups than in the other. By comparing controls under Aripiprazole and under Placebo, we concluded
that Aripiprazole appears to improve the distinguishability between patients and controls primarily through its
effects on community structure in controls (i.e., healthy individuals). Our observations that Aripiprazole primarily
affects community structure in controls is consistent with the results of [32], who reported that Aripiprazole has a
radical effect on the organization of healthy brain networks but decreases the performance of healthy individuals at
cognitive tasks.
Our results for the drug Sulpiride are mixed. We found that under Sulpiride, patients are slightly closer to
controls than they are under Aripiprazole or Placebo. This is also consistent with [32], and it suggests that Sulpiride
has a mild effect on community structure that is appreciably larger than, for instance, the effect of Aripiprazole on
community structure in patients (which we observed to be very small). We have not been able to clearly establish
the origin of this effect, as our intra-group comparisons suggest that community structure in both controls and
patients is mostly unaltered by Sulpiride.
Mesoscale network structures such as community structure are well-known to be important for functional brain
networks [2], and network analysis more generally is a useful approach for disentangling structure, function, and
their complex interrelations in the brain. In the present paper, we used community structure and mesoscopic
response functions for a classification task in time-independent, monolayer functional brain networks. Extending
these results and analysis to time-dependent and multilayer settings [46,47] is an interesting open problem.
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A Appendix: Metric properties of d1
In this appendix, we state and prove a theorem on the metric properties of d1 (which we defined in Eq. (3)) that is
slightly more general than the one that we used in the main text. The result in the main text follows from it as a
trivial corollary.
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Theorem 1. Let Sn(E) be the set of n× n square matrices with entries of 0 or 1 (i.e., “binary matrices”), where
the number E of 1 entries satisfies E < n2. Let A ,B ∈ Sn(E) be two arbitrary elements of the set. Consider the
function d1 defined by
d1 : Sn(E)× Sn(E)→ [0, 1] , d1(A,B) = 1− 1
E
n∑
i=1
n∑
j=1
AijBij . (9)
The function d1 is a metric.
The definition in (9) for d1 is slightly more general than the one in Eq. 3, as here we are not assuming that (1)
A and B are symmetric or that (2) there are no 1 entries in the diagonal (so E is the number of 1 entries). In the
main text, we imposed some restrictions on E that are not present here: we used E to denote the number of edges
in an associated network, so for Eq. 3 (which is designed to deal with unweighted, undirected adjacency matrices
with no self-loops), one needs either to restrict to the case in which there are no 1 entries in the main diagonal and
then do the relabeling E → E/2 or to relabel the summation indices with ∑ni=1∑nj=1 →∑i>j . The theorem that
we stated in the main text is thus a special case of Theorem 1.
Proof. To prove that d1 is a metric, we need to prove four properties: nonnegativity, identity of indiscernibles,
symmetry, and the triangle inequality. The first three properties are satisfied trivially:
1. Nonnegativity: By construction,
∑n
i=1
∑n
j=1AijBij ≤ E, so d1(A,B) ≥ 0.
2. Identity of indiscernibles: d1(A,B) = 0 ⇔
∑n
i=1
∑n
j=1AijBij = E. However, by definition, the matrices are
binary and have E entries with the value 1, so
∑n
i=1
∑n
j=1AijBij = E ⇔ A = B.
3. Symmetry: This arises trivially from the commutative property of the scalar product: AijBij = BijAij .
To prove the fourth property (the triangle inequality), we need to show that
for all A,B,C ∈ Sn(E) , d1(A,B) + d1(B,C) ≥ d1(A .C) . (10)
This part is more subtle, and we need to break the proof into a couple of steps. We start by defining a matrix
δ-perturbation.
Definition 1. (Matrix δ-perturbation) Let A ∈ Sn(E), and let δ be a positive integer such that 0 < δ < E.
The matrix A˜(δ) is a δ-perturbation of A if A˜(δ) is constructed by taking A and changing the position of δ of the 1
entries.
To illustrate this definition, we show an example of a matrix and a 1-perturbation of that matrix in S3(3):
Z =
1 0 01 0 0
0 1 0
 , Z˜(1) =
0 0 11 0 0
0 1 0
 . (11)
It is clearly the case that A˜(δ) ∈ Sn(E). It is also true that
n∑
i=1
n∑
j=1
AijA˜
(δ)
ij = E − δ ⇒ d1(A˜(δ),A) = δ/E .
Starting from an arbitrary element of Sn(E), one can reach any other element by applying an appropriate δ-
perturbation. Therefore, equipped with the δ-perturbation, Sn(E) is a unary system. This property is important
for guaranteeing completeness.
To prove Eq. (10), it is equivalent to prove that
for all A,B,C ∈ Sn(E) , X :=
n∑
i=1
n∑
j=1
(AijBij +BijCij −AijCij) ≤ E .
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We are ready to prove this latter inequality. We start with a degenerate case. Consider an arbitrary A ∈ Sn(E)
and set A = B = C; in this case, X =∑ni=1∑nj=1AijAij = E ≤ E.
To generate all possible triples of matrices {A,B,C}, without loss of generality, we now consider an arbitrary
(but fixed) A ∈ Sn(E); and we use δ-perturbations to generate all instances of B and C. That is,
B := A˜(δb), C := A˜(δc), δb, δc ≥ 0 .
All possible triples can be expressed in this form.
Let’s evaluate X . The first term is
n∑
i=1
n∑
j=1
AijBij =
n∑
i=1
n∑
j=1
AijA˜
(δb)
ij = E − δb ;
the second term is
n∑
i=1
n∑
j=1
BijCij =
n∑
i=1
n∑
j=1
A˜
(δb)
ij A˜
(δc)
ij ;
and the third term is
n∑
i=1
n∑
j=1
AijCij =
n∑
i=1
n∑
j=1
AijA˜
(δc)
ij = E − δc .
We need to separately consider the cases in which a pair of matrices experience the same perturbation or different
perturbations. In the usual case, δb 6= δc, so there is at least an offset of |δb − δc|. Consequently,
n∑
i=1
n∑
j=1
A˜
(δb)
ij A˜
(δc)
ij ≤ E − |δb − δc| . (12)
If, however, δb = δc (i.e., both δ-perturbations are the same), the right-hand-side of Eq. (12) is instead given by E.
Altogether, this yields the following:
X ≤ E − δb + E − |δb − δc| − E + δc = E + (δc − δb)− |δb − δc| .
Three possibilities emerge:
1. If δb = δc, then X ≤ E.
2. If δb < δc, then |δb − δc| = δc − δb, so X ≤ E.
3. If δb > δc, then |δb − δc| = δb − δc, so X ≤ E + 2(δc − δb) < E.
This concludes the proof. 
B Appendix: Network Component Sizes
As we discussed in Section 3.2, half of our networks — 30 out of 60 — consist of two or more components after
thresholding. However, even in these cases, the largest connected component of each network consists of almost the
entire network. In Table 1, we show the number of components and component sizes for each of the 60 networks.
Table 1: Number of components and component sizes of each of the 60 networks. We denote treatment under Aripiprazole by
“A”, treatment under Sulpiride by “S”, and treatment under Placebo by “P”.
Subject Number of Components Component Sizes
18
Control 1 (A) 6 {293,1,1,1,1,1}
Control 3 (A) 4 {295,1,1,1}
Control 4 (A) 5 {293,2,1,1,1}
Control 5 (A) 20 {268,6,5,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1}
Control 6 (A) 2 {297,1}
Control 7 (A) 3 {296,1,1}
Control 9 (A) 4 {295,1,1,1}
Control 11 (A) 2 {297,1}
Control 12 (A) 6 {292,2,1,1,1,1}
Control 13 (A) 6 {292,2,1,1,1,1}
Control 15 (A) 2 {297,1}
Control 1 (P) 1 298
Control 3 (P) 2 {297,1}
Control 4 (P) 1 298
Control 5 (P) 2 {297,1}
Control 6 (P) 5 {289,3,3,2,1}
Control 7 (P) 4 {295,1,1,1}
Control 9 (P) 2 {297,1}
Control 11 (P) 1 298
Control 12 (P) 4 {294,2,1,1}
Control 13 (P) 4 {295,1,1,1}
Control 15 (P) 1 298
Control 1 (S) 1 298
Control 3 (S) 2 {297,1}
Control 4 (S) 1 298
Control 5 (S) 1 298
Control 6 (S) 3 {296,1,1}
Control 7 (S) 1 298
Control 9 (S) 1 298
Control 11 (S) 2 {297,1}
Control 12 (S) 1 298
Control 13 (S) 3 {296,1,1}
Control 15 (S) 1 298
Patient 1 (A) 2 {297,1}
Patient 2 (A) 1 298
Patient 4 (A) 1 298
Patient 6 (A) 1 298
Patient 7 (A) 2 {297,1}
Patient 8 (A) 7 {291,2,1,1,1,1,1}
Patient 9 (A) 1 298
Patient 10 (A) 1 298
Patient 12 (A) 1 298
Patient 1 (P) 1 298
Patient 2 (P) 1 298
Patient 4 (P) 1 298
Patient 6 (P) 1 298
Patient 7 (P) 2 {297,1}
Patient 8 (P) 7 {292,1,1,1,1,1,1}
Patient 9 (P) 1 298
Patient 10 (P) 3 {296,1,1}
Patient 12 (P) 1 298
Patient 1 (S) 1 298
Patient 2 (S) 2 {297,1}
Patient 4 (S) 1 298
Patient 6 (S) 1 298
Patient 7 (S) 1 298
19
Patient 8 (S) 5 {294,1,1,1,1}
Patient 9 (S) 1 298
Patient 10 (S) 1 298
Patient 12 (S) 1 298
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